Rupa Mazumder | Toxicology and Pharmaceutical Science | Best Researcher Award

Best Researcher Award

Rupa Mazumder
Noida Institute of Engineering And Technology

Rupa Mazumder
Affiliation Noida Institute of Engineering And Technology
Country India
Scopus ID 7005832705
Documents 211
Citations 1,412
h-index 18
Subject Area Toxicology and Pharmaceutical Science
Event International Invention Awards
ORCID 0000-0002-1888-548X

Rupa Mazumder is a researcher affiliated with the Noida Institute of Engineering And Technology, India, whose documented scholarly profile is associated with toxicology and pharmaceutical science. The supplied Scopus record reports 211 documents, 1,412 citations, and an h-index of 18, providing a bibliometric basis for considering the researcher within an academic recognition framework. [1]

Abstract

Rupa Mazumder is an India-based researcher affiliated with the Noida Institute of Engineering And Technology and associated with the subject area of Toxicology and Pharmaceutical Science. The supplied bibliometric profile records 211 scholarly documents, 1,412 citations, and an h-index of 18. These indicators provide measurable evidence of sustained research activity and scholarly visibility. Her profile is considered in relation to the Best Researcher Award under the International Invention Awards framework. Assessment of researcher recognition may consider publication productivity, citation influence, research continuity, subject expertise, and the broader relevance of scientific contributions. Bibliometric information should be interpreted alongside verified qualitative evidence and individual research outputs for balanced academic evaluation.

Keywords

Rupa Mazumder; Best Researcher Award; Toxicology; Pharmaceutical Science; Drug Research; Pharmacology; Research Impact; Scholarly Publications; Citation Analysis; h-index; Scientific Research; International Invention Awards.

Introduction

Researcher recognition in pharmaceutical and toxicological sciences commonly involves consideration of scholarly productivity, research quality, citation performance, and sustained engagement with scientific questions. Bibliometric indicators can provide a structured quantitative perspective, although they do not independently establish the originality or practical significance of individual studies. The available profile for Rupa Mazumder presents a substantial publication and citation record that can be examined as part of a broader academic assessment. [1] Standardized researcher identifiers such as Scopus Author ID and ORCID can also assist in distinguishing scholarly outputs and improving the reliability of attribution. [2]

Research Profile

The supplied profile identifies Rupa Mazumder with the Noida Institute of Engineering And Technology in India and places the research activity within Toxicology and Pharmaceutical Science. The reported Scopus Author ID is 7005832705, while the associated ORCID is 0000-0002-1888-548X. These persistent identifiers provide complementary mechanisms for connecting scholarly records with an individual researcher and can support verification across academic databases. [1] [2]

Research Contributions

Within toxicology and pharmaceutical science, research contributions may encompass the investigation of drug effects, safety, pharmacological mechanisms, toxicological responses, therapeutic development, and related biomedical questions. The available information does not provide a complete thematic inventory of Rupa Mazumder’s individual studies, so specific scientific claims should be based on verified publication records rather than inferred solely from bibliometric indicators. The documented publication volume nevertheless indicates sustained participation in scholarly research. [1]

Publications

The supplied Scopus information records 211 documents associated with the researcher profile. Publication counts are useful for describing research productivity but should be evaluated with attention to document type, authorship, journal quality, research field, chronology, and subject relevance. A complete publication assessment would require examination of the underlying indexed records and individual bibliographic metadata. The reported document count is therefore presented as a profile-level bibliometric indicator rather than as an independent measure of research quality. [1]

Research Impact

The supplied profile reports 1,412 citations and an h-index of 18. Citation indicators can help describe the visibility and scholarly uptake of published research, while the h-index combines productivity and citation dimensions into a single metric. Such measures vary across disciplines, career stages, database coverage, and publication practices and should therefore be interpreted within appropriate academic context. [1] Citation-based assessment is strongest when complemented by qualitative evidence concerning originality, methodological contribution, collaboration, and influence on subsequent research.

Award Suitability

The available bibliometric information provides a relevant quantitative foundation for consideration for the Best Researcher Award. The combination of 211 reported documents, 1,412 citations, and an h-index of 18 indicates an established scholarly record within the supplied profile. [1] Final award suitability should, however, be determined through verification of the researcher identity, publication record, research quality, originality, professional contributions, and alignment with the applicable award criteria. The profile therefore supports consideration without implying that bibliometric measures alone determine award outcome.

Conclusion

Rupa Mazumder’s supplied academic profile documents substantial scholarly activity in the field of Toxicology and Pharmaceutical Science, with 211 documents, 1,412 citations, and an h-index of 18. These indicators establish a useful quantitative basis for academic recognition while requiring contextual interpretation. [1] Verification through persistent researcher identifiers, indexed publications, and qualitative evidence can strengthen the assessment. On the information provided, the profile presents a credible basis for consideration under the Best Researcher Award category of the International Invention Awards.

References

  1. Elsevier. (n.d.). Scopus author details: Rupa Mazumder, Author ID 7005832705. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=7005832705
  2. ORCID. (n.d.). ORCID record: Rupa Mazumder, ORCID 0000-0002-1888-548X. ORCID.
    https://orcid.org/0000-0002-1888-548X
  3. Journal article. (2026).Preparations, Applications, Patents, and Marketed Formulations of Nanoemulsions – A Comprehensive Review.
    http://dx.doi.org/10.2174/0122117385325186240912110731
  4. Journal article. (2025). A Comprehensive Investigation on the Role of Bioactives on DYRK1A to Avert Alzheimer’s Disease.
    https://doi.org/10.18311/jnr/2025/49903
  5. International Invention Awards. (2026. ). Official award website.
    https://inventionawards.org/

Shiva Vairale | CSIR – National Chemical Laboratory | Best Researcher Award

Best Researcher Award

Shiva Vairale
CSIR – National chemical Laboratory

Shiva Vairale
Affiliation CSIR – National Chemical Laboratory
Country India
Scopus ID 60050407800
Documents 6
Citations 9
h-index 3
Subject Area Drug Discovery
Event International Invention Awards
Google Scholar Rgn4SCoAAAAJ

Shiva Vairale is a researcher affiliated with the CSIR – National Chemical Laboratory in India, with research interests associated with biochemical sciences and drug discovery. Publicly indexed research records connect his work with bioactive molecules, natural products, biological macromolecules, antimicrobial investigations, and pharmacological applications. His research activities include collaborative studies addressing biologically relevant compounds and their potential therapeutic significance. Available publication records identify contributions to peer-reviewed research involving sericin-based nanotherapeutics and insect-derived metabolites, illustrating an interdisciplinary orientation spanning biochemistry, pharmacology, and translational drug-discovery research. [1]

Abstract

Shiva Vairale is a researcher at CSIR – National Chemical Laboratory whose documented work focuses on biochemical sciences, natural bioactive compounds, and drug discovery. His research profile includes investigations of biologically active molecules, therapeutic mechanisms, antimicrobial activity, and emerging nanotherapeutic approaches. Published work has addressed sericin-based formulations for anti-urolithiatic and antibacterial applications, while a recent review examines insect-derived metabolites and their pharmacological potential in modern drug discovery. These studies reflect an interdisciplinary research direction connecting biochemistry, natural products, pharmacology, molecular mechanisms, and translational applications. His indexed research record provides measurable indicators of scholarly activity and citation-based visibility.

Keywords

Shiva Vairale, Best Researcher Award, drug discovery, biochemical sciences, natural products, insect-derived metabolites, pharmacology, bioactive compounds, sericin nanotherapeutics, antimicrobial research, therapeutic applications, CSIR-National Chemical Laboratory, India.

Introduction

Drug discovery increasingly integrates natural-product chemistry, molecular biology, pharmacology, and advanced formulation strategies to identify biologically useful compounds. Within this multidisciplinary landscape, Vairale’s documented research is associated with the investigation of bioactive substances and their therapeutic relevance. His work at CSIR-National Chemical Laboratory places these activities within an established Indian research environment focused on chemical and biological sciences. [2] Recent publications further demonstrate engagement with natural metabolites and biological macromolecules as potential sources of pharmacological applications. [3]

Research Profile

Vairale’s research profile is situated primarily within biochemical sciences and drug discovery. Publicly available institutional and bibliographic information associates him with the Biochemical Sciences Division of CSIR-National Chemical Laboratory and with research involving bioactive compounds, biological assays, natural metabolites, and therapeutic applications. His academic record also places his doctoral research within biological sciences, supporting an interdisciplinary trajectory connecting chemical and biological investigation. [2]

Research Contributions

A documented contribution involves research on sericin-based nanotherapeutics, examining sericin and related nanoparticle formulations for anti-urolithiatic and antibacterial applications. The study combines biological macromolecules, nanotechnology, characterization, and pharmacological assessment. [1] Another contribution is a review of insect-derived metabolites in drug discovery, covering chemically diverse metabolites and their biological mechanisms while considering their translational relevance to pharmacotherapy. [4]

Publications

Vairale has contributed to peer-reviewed publications spanning natural products, biological macromolecules, antimicrobial research, and drug discovery. A notable publication is Sericin-based nanotherapeutics: A dual-action biological macromolecule for anti-urolithiatic and antibacterial applications, published in the International Journal of Biological Macromolecules in 2025 with DOI 10.1016/j.ijbiomac.2025.146763. [1] His 2026 review, Insect derived metabolites in drug discovery: Pharmacological potential, mechanisms, and translational challenges, appeared in Pharmacological Research – Natural Products, DOI 10.1016/j.prenap.2026.100808. [4]

Research Impact

The research addresses scientific questions relevant to therapeutic discovery, particularly the identification and characterization of biologically active substances. Work on sericin-based systems explores potential applications against urolithiasis and bacterial activity, while research concerning insect metabolites considers their broader pharmacological potential. These themes are relevant to continuing efforts to identify new biological resources and mechanisms for therapeutic development. The supplied bibliometric profile records six documents, nine citations, and an h-index of three. [1]

Award Suitability

For recognition under a Best Researcher Award category, the documented record provides evidence of peer-reviewed research activity, interdisciplinary subject engagement, and identifiable contributions to drug-discovery research. Relevant evidence includes publications involving biological macromolecules and natural metabolites, collaboration across research groups, and indexed bibliometric indicators supplied for this profile. The award record should be considered alongside the complete nomination materials and applicable evaluation criteria of the International Invention Awards. [5]

Conclusion

Shiva Vairale’s documented research activity reflects an interdisciplinary focus on biochemical sciences and drug discovery, with published work addressing sericin-based nanotherapeutics and insect-derived metabolites. His research connects natural bioactive resources with pharmacological investigation and potential therapeutic applications. The available bibliometric information and publication record provide a structured basis for describing his scholarly profile and its relevance to research recognition within the International Invention Awards.

References

  1. Elsevier. (n.d.). Scopus Author Details: Author ID 60050407800. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=60050407800
  2. Review article. (2026). Insect derived metabolites in drug discovery: Pharmacological potential, mechanisms, and translational challenges.
    https://doi.org/10.1016/j.prenap.2026.100808
  3. Research article. (2025). Sericin-based nanotherapeutics: A dual-action biological macromolecule for anti-urolithiatic and antibacterial applications.
    https://doi.org/10.1016/j.ijbiomac.2025.146763
  4. Google Scholar. (n.d.). Google Scholar author profile: Shiva Vairale. Google Scholar.
    https://scholar.google.com/citations?hl=en&user=Rgn4SCoAAAAJ
  5. International Invention Awards. (2026). International Invention Award.
    https://inventionawards.org/

Jin Hyoung Kang | Clinical Development of Bispecific Antibody | Research Excellence Award

After Completing the Registration Process, your Biography will be displayed here.

Register by using your Entry ID: 26083

Register Here

 

Assoc. Prof. Dr. Jessica Fleming | Molecular Biomarkers | Best Researcher Award

Assoc. Prof. Dr. Jessica Fleming | Molecular Biomarkers | Best Researcher Award

The Ohio State University, United States.

Dr. Jessica L. Fleming, PhD, is an accomplished radiobiologist at the James Comprehensive Cancer Center, The Ohio State University. With over a decade of experience in translational oncology research, she specializes in molecular biomarkers and radiation therapy innovations. Dr. Fleming plays a key role in collaborative clinical and research initiatives, especially in glioma and FLASH radiotherapy. She is also a co-founder and former CEO of the Cap City Biohackers, demonstrating her entrepreneurial edge in biomedical innovation.

Profile

Scopus

πŸŽ“ Education

Dr. Fleming earned her PhD in Molecular, Cellular, and Developmental Biology from The Ohio State University in 2012, following a BS in Biology, Cum Laude, from Ashland University in 2006. Her strong academic foundation was supported by multiple fellowships and research opportunities during her undergraduate and graduate studies.

πŸ§ͺ Experience

Dr. Fleming currently serves as an Associate Radiobiologist at OSU, working with Dr. Arnab Chakravarti. Her journey at OSU began as a graduate student, advancing through postdoctoral research and senior research associate roles. She has led cutting-edge radiobiological studies and was integral to several major clinical protocols. Beyond academia, she was the CEO and Co-Founder of Cap City Biohackers, reflecting her commitment to science outreach and innovation.

πŸ”¬ Research Interests

Radiation oncology and molecular oncology, particularly adult gliomas and biomarkers

FLASH radiotherapy, clinical translation, and toxicity modeling

Tumor heterogeneity and resistance mechanisms

Translational research bridging lab discoveries and patient care

πŸ† Awards & Honors

πŸ₯‡ 2024 ASTRO Annual Meeting Abstract Award

πŸ… Columbus CEO Future 50 Award (2020)

πŸŽ– Best of ASTRO & Basic/Translational Science Abstract Award (2018)

πŸŽ“ Alumni Grants for Graduate Research (2012)

🧬 NSF REU Fellow (2005)

🌟 Track & Field Athletic Scholar and Presidential Scholar (2002–2006)

πŸ“š Selected Publications

Here are some of Dr. Fleming’s key publications, with citation and access details:

Fleming JL et al. (2025) – Comprehensive Molecular Analysis in NRG Oncology/RTOG 9813 – Int J Radiat Oncol Biol Phys (Accepted)

Manring HR, Fleming JL et al. (2025) – FLASH Radiotherapy: From In Vivo Data to Clinical Translation – Hematol Oncol Clin N Am (PMID: 39828472)

Fleming JL, Chakravarti A. (2025) – Molecular Biomarkers in Adult Lower-Grade Gliomas – Cancer J, 31(1): e0758. (PMID: 39841423)
➀ Cited by: 2 articles

Kotecha R, Schiff D, Chakravarti A, Fleming JL et al. (2024) – Management of IDH-Mutated Gliomas – J Clin Oncol, 42(21): 2588-2598. (PMID: 38833641)
➀ Cited by: 15 articles

Becker AP, Becker V, McElroy J, Fleming J et al. (2024) – HMGB2 as Biomarker in Astrocytomas – Cancers (Basel), 16(8): 1516. (PMID: 38672598)
➀ Cited by: 7 articles